In this episode of On The Line, BioCanRx President and CEO Stephanie Michaud joins Matt Gurney for a conversation about one of the biggest problems facing Canadian health care: Canada produces world-class medical research, but too often struggles to turn those discoveries into treatments that actually reach Canadian patients.
Stephanie explains why it can take so long for the newest and most promising therapies to make their way into the Canadian health-care system — and why so much science developed by Canadian researchers ultimately ends up being commercialized in the United States. Canada has extraordinary researchers and institutions. So why do we keep losing the economic and medical benefits of their work?
This episode is brought to you by the Forest Products Association of Canada. Budget season in Ottawa is filled with asks for new programs, new tax measures and new investment. But for Canada’s forest products sector, the biggest opportunity for growth doesn’t require new spending — it requires smarter rules. Regulatory inefficiencies are costing the average Canadian mill an estimated one million dollars a year each. That’s money that could be reinvested in workers, communities, and modernization instead. The Forest Sector Transformation Task Force gave Ottawa a clear playbook. As the federal budget takes shape, the fastest way to unlock private investment is to remove the made-in-Canada barriers standing in the way. Learn more at
[FPAC.ca].
Matt and Stephanie also discuss what it would take for Canada to become more independent of the United States in biotechnology and health care. If Canadians really want to get their elbows up, this is one area where the country already has many of the ingredients it needs. They look at opportunities to work with international partners, build domestic capacity and create a system capable of taking Canadian discoveries from the laboratory all the way to Canadian patients.
And, unusually for On The Line, there’s some optimism. Stephanie believes Canada has a genuine opportunity to build on its existing strengths and become a global leader in biotechnology — creating economic opportunities while also helping Canadians survive terrible diseases and live longer, healthier lives.
This episode is also brought to you by Cameco. Building Canada’s energy future means creating jobs for Canadian workers. That’s why the AP1000 reactor is the right choice for Canada: it is already operating and ready to deliver the power we need. Choosing the AP1000 means a reactor built by Canadians, creating skilled jobs in construction, fabrication and the trades while keeping more investment and economic benefits here at home. If we are serious about creating Canadian jobs and strengthening our economy, the choice is clear. To learn more, visit
[ap1000.cameco.com].
Disclosures x 2: BioCanRx has been and remains a sponsor of The Line. This was an interview we wanted to do because of what Matt Gurney learned while his wife battled a devastating cancer diagnosis; an employee at BioCanRx is an old friend of Matt’s and offered his help soon after the diagnosis, which is how The Line and BioCanRx began speaking in the first place. For the record: BioCanRx did not seek or receive any editorial control over this interview, was not provided questions in advance, nor asked for them, and requested no changes to the finished product. For further transparency, the only edits to this podcast were to cover your intrepid host choking while sipping water, like the seasoned broadcast professional he is, and a doorbell ringing. Exciting times!
We hope you enjoy this episode, and as always, like and subscribe.
YouTube:
Video goes live at 7 p.m Eastern/5 Mountain.
Spotify:
Apple:
Enjoy the episode! Talk to you soon.
The Line is entirely reader and advertiser funded. No federal subsidies, no bailouts. If you value our work, please consider supporting us by subscribing or making a donation. Donations are not subscriptions and do not unlock paywalled content, but they help keep The Line independent
To contact The Line with a general inquiry or comment, please email info@readtheline.ca. For other ways to connect with us or to follow us on social media, please see our LinkTree.
